Physician profile
Christopher M Belletieri
NPI 1174562904
$11,401.54
in general payments reported to CMS, 2019-2025
36 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $4,131 · 2021: $2,484 · 2022: $552 · 2023: $961 · 2024: $1,195 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,905.42 | 2020 | |
| Abbvie INC. | $2,062.15 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Abbott Laboratories | $890.16 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $559.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $512.03 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $495.27 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $470.70 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $403.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $349.80 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $212.25 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $191.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.99 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $160.76 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $138.01 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.24 | 2019-2024 | Jardiance |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Belletieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.